Horizon's newest CHOSOURCE cell line eliminates the cell’s natural fucosylation activity to increase therapeutic antibody efficacy and potency. Elimination of core fucose on the Fc N-glycan of antibodies enhances antibody-dependent cellular cytotoxicity (ADCC) activity of immune effector cells by increasing antibody binding to the FcgRIIIa receptor present on effector cells.
Afucosylated antibody benefits:
- Increase therapeutic efficacy of antibodies for use in oncology, infectious and autoimmune diseases
- Improve drug potency, expand the therapeutic window and reduce dosage requirements
- Reduce dosage requirements and undesirable side effects of your therapeutic antibody treatments
Why use CHOSOURCE CHO-K1 ADCC+ Cell Line from Horizon?
- Proven track record with existing CHOSOURCE CHO-K1 GS KO cell line
- Over 100+ licenses and multiple regulatory filings worldwide
- Adaptable platform - can be successfully used with:
- Various vector systems
- Multiple media and processes
- Non-royalty bearing with no license tie-ins to specific vendors, technologies, or service providers
CHOSOURCE CHO-K1 ADCC+ Poster
Discover how the CHOSOURCE CHO-K1 ADCC+ cell line increases Antibody Dependent Cellular Cytotoxicity (ADCC) making it a valuable tool in the production of biotherapeutics for oncology, anti-infectives and Auto-immune diseases.
Contact us to find out more
© 2024 Horizon Discovery Ltd., Company Registration Number 08921143